206650 — EuBiologics Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩507bn
- KR₩505bn
- KR₩69bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 9,734 | 53,088 | 31,545 | 11,044 | 9,897 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2,787 | 6,383 | 3,917 | 5,547 | 12,099 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 21,497 | 71,407 | 53,720 | 41,139 | 41,764 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 64,679 | 68,538 | 70,046 | 72,815 | 70,096 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 92,765 | 155,955 | 150,438 | 162,066 | 151,806 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 27,491 | 35,197 | 17,282 | 24,624 | 25,699 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 57,813 | 59,079 | 30,439 | 37,556 | 40,433 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 34,952 | 96,877 | 119,999 | 124,510 | 111,373 |
Total Liabilities & Shareholders' Equity | 92,765 | 155,955 | 150,438 | 162,066 | 151,806 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |